Rituximab Failed to Improve Nephrotic Syndrome in Renal Transplant Patients With Recurrent Focal Segmental Glomerulosclerosis
Open Access
- 1 January 2008
- journal article
- case report
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 8 (1), 222-227
- https://doi.org/10.1111/j.1600-6143.2007.02021.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of ActionAmerican Journal of Transplantation, 2006
- Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndromePediatric Nephrology, 2005
- Treatment of focal segmental glomerulosclerosisExpert Opinion on Pharmacotherapy, 2005
- New Insights into the Pathogenesis and the Therapy of Recurrent Focal GlomerulosclerosisAmerican Journal of Transplantation, 2005
- Outcomes after renal transplantation for FSGS in childrenPediatric Transplantation, 2004
- PROTEINURIA AFTER INJECTION OF HUMAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS FACTOR12Transplantation, 2002
- Circulating Factor Associated with Increased Glomerular Permeability to Albumin in Recurrent Focal Segmental GlomerulosclerosisNew England Journal of Medicine, 1996
- Effect of Plasma Protein Adsorption on Protein Excretion in Kidney-Transplant Recipients with Recurrent Nephrotic SyndromeNew England Journal of Medicine, 1994
- Recurrent focal glomerulosclerosis: Natural history and response to therapyAmerican Journal Of Medicine, 1992
- Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: Analysis of incidence and risk factors in 59 allograftsPediatric Nephrology, 1990